| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Contrast Media | 29 | 2024 | 1499 | 3.940 |
Why?
|
| Nanoparticles | 19 | 2022 | 585 | 3.270 |
Why?
|
| Liposomes | 30 | 2019 | 704 | 2.710 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2022 | 153 | 1.600 |
Why?
|
| Gadolinium | 7 | 2019 | 169 | 1.360 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2024 | 7895 | 1.350 |
Why?
|
| Drug Carriers | 12 | 2012 | 336 | 1.320 |
Why?
|
| Placenta | 5 | 2022 | 561 | 1.280 |
Why?
|
| Optical Imaging | 3 | 2018 | 158 | 1.230 |
Why?
|
| Fluorocarbons | 2 | 2018 | 63 | 1.190 |
Why?
|
| Indocyanine Green | 3 | 2023 | 125 | 1.180 |
Why?
|
| Alzheimer Disease | 6 | 2024 | 818 | 1.170 |
Why?
|
| Computer-Aided Design | 2 | 2020 | 76 | 1.120 |
Why?
|
| Models, Anatomic | 2 | 2020 | 146 | 1.080 |
Why?
|
| Tomography, X-Ray Computed | 14 | 2022 | 7784 | 1.060 |
Why?
|
| Triiodobenzoic Acids | 5 | 2021 | 69 | 1.050 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2021 | 908 | 0.930 |
Why?
|
| Drug Delivery Systems | 7 | 2012 | 661 | 0.870 |
Why?
|
| Plaque, Amyloid | 3 | 2020 | 63 | 0.790 |
Why?
|
| X-Ray Microtomography | 3 | 2021 | 136 | 0.780 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 2 | 2018 | 85 | 0.760 |
Why?
|
| Angiography | 2 | 2021 | 350 | 0.740 |
Why?
|
| Cerebrovascular Disorders | 1 | 2021 | 153 | 0.720 |
Why?
|
| Atherosclerosis | 2 | 2022 | 912 | 0.700 |
Why?
|
| Fluorine | 1 | 2018 | 22 | 0.640 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 145 | 0.630 |
Why?
|
| Amyloid | 2 | 2020 | 91 | 0.630 |
Why?
|
| Hindlimb | 1 | 2018 | 111 | 0.620 |
Why?
|
| Insulin | 3 | 2012 | 1486 | 0.620 |
Why?
|
| Ethers | 1 | 2018 | 13 | 0.620 |
Why?
|
| Animals | 49 | 2023 | 62048 | 0.610 |
Why?
|
| Fluorine-19 Magnetic Resonance Imaging | 1 | 2018 | 6 | 0.610 |
Why?
|
| Integrin alpha4beta1 | 1 | 2018 | 46 | 0.610 |
Why?
|
| Phantoms, Imaging | 4 | 2018 | 1330 | 0.600 |
Why?
|
| Aortography | 2 | 2021 | 172 | 0.590 |
Why?
|
| Computer Simulation | 2 | 2021 | 1570 | 0.550 |
Why?
|
| Amyloid beta-Protein Precursor | 3 | 2020 | 133 | 0.550 |
Why?
|
| Skull | 1 | 2018 | 251 | 0.550 |
Why?
|
| Mice | 28 | 2023 | 35597 | 0.530 |
Why?
|
| Disease Models, Animal | 14 | 2022 | 7383 | 0.530 |
Why?
|
| Blood-Brain Barrier | 2 | 2014 | 251 | 0.510 |
Why?
|
| Radiography, Thoracic | 3 | 2015 | 477 | 0.510 |
Why?
|
| Pulmonary Blastoma | 1 | 2015 | 21 | 0.500 |
Why?
|
| Neuroblastoma | 2 | 2021 | 705 | 0.490 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2014 | 14 | 0.480 |
Why?
|
| Aorta | 3 | 2021 | 670 | 0.480 |
Why?
|
| Presenilin-1 | 2 | 2020 | 57 | 0.470 |
Why?
|
| Computer Peripherals | 1 | 2013 | 5 | 0.460 |
Why?
|
| Ribonuclease III | 1 | 2015 | 182 | 0.460 |
Why?
|
| Cerebral Arteries | 1 | 2014 | 100 | 0.450 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2015 | 256 | 0.430 |
Why?
|
| Stroke | 1 | 2021 | 1058 | 0.430 |
Why?
|
| Musculoskeletal Diseases | 1 | 2013 | 96 | 0.420 |
Why?
|
| Nanostructures | 4 | 2008 | 101 | 0.420 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2011 | 551 | 0.410 |
Why?
|
| Medical Oncology | 2 | 2023 | 1465 | 0.410 |
Why?
|
| Vascular Diseases | 1 | 2015 | 235 | 0.410 |
Why?
|
| Chest Pain | 1 | 2013 | 173 | 0.410 |
Why?
|
| Nanomedicine | 1 | 2012 | 53 | 0.390 |
Why?
|
| Delayed-Action Preparations | 3 | 2007 | 190 | 0.390 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 514 | 0.390 |
Why?
|
| Amyloid beta-Peptides | 1 | 2012 | 226 | 0.370 |
Why?
|
| Pediatrics | 1 | 2020 | 1189 | 0.370 |
Why?
|
| Coronary Angiography | 1 | 2013 | 533 | 0.360 |
Why?
|
| Aortic Diseases | 1 | 2013 | 196 | 0.360 |
Why?
|
| Lung | 4 | 2007 | 3300 | 0.360 |
Why?
|
| Neuroimaging | 3 | 2021 | 402 | 0.350 |
Why?
|
| Boronic Acids | 1 | 2012 | 354 | 0.350 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 585 | 0.340 |
Why?
|
| Mice, Transgenic | 6 | 2022 | 4223 | 0.310 |
Why?
|
| Brain | 4 | 2024 | 4213 | 0.310 |
Why?
|
| Immunotherapy | 3 | 2023 | 3557 | 0.310 |
Why?
|
| Health Care Costs | 1 | 2013 | 699 | 0.310 |
Why?
|
| Particle Size | 6 | 2009 | 188 | 0.300 |
Why?
|
| Rats | 13 | 2020 | 6525 | 0.290 |
Why?
|
| Iohexol | 2 | 2007 | 56 | 0.290 |
Why?
|
| Administration, Inhalation | 5 | 2007 | 300 | 0.280 |
Why?
|
| Polyethylene Glycols | 6 | 2012 | 654 | 0.270 |
Why?
|
| Aerosols | 2 | 2007 | 150 | 0.270 |
Why?
|
| Models, Biological | 4 | 2011 | 3194 | 0.270 |
Why?
|
| Systemic Inflammatory Response Syndrome | 3 | 2022 | 192 | 0.270 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 90 | 0.270 |
Why?
|
| Neoplasms | 7 | 2023 | 15920 | 0.270 |
Why?
|
| Cardiology | 1 | 2012 | 511 | 0.260 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 1174 | 0.260 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 1252 | 0.250 |
Why?
|
| Glucose | 2 | 2012 | 1220 | 0.250 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2017 | 2212 | 0.230 |
Why?
|
| Humans | 40 | 2024 | 270806 | 0.230 |
Why?
|
| Receptors, Cell Surface | 2 | 2005 | 904 | 0.230 |
Why?
|
| Ligands | 4 | 2021 | 1016 | 0.230 |
Why?
|
| Mice, Knockout | 3 | 2021 | 5731 | 0.230 |
Why?
|
| Rheology | 1 | 2003 | 47 | 0.220 |
Why?
|
| Folic Acid | 2 | 2006 | 369 | 0.220 |
Why?
|
| Microspheres | 1 | 2003 | 238 | 0.210 |
Why?
|
| Tumor Microenvironment | 3 | 2021 | 3031 | 0.210 |
Why?
|
| Tomography, Spiral Computed | 1 | 2003 | 128 | 0.210 |
Why?
|
| Child | 12 | 2023 | 30547 | 0.210 |
Why?
|
| Adventitia | 1 | 2022 | 6 | 0.200 |
Why?
|
| Female | 22 | 2022 | 148969 | 0.190 |
Why?
|
| Indans | 1 | 2021 | 70 | 0.190 |
Why?
|
| Vimentin | 1 | 2022 | 255 | 0.190 |
Why?
|
| Bronchi | 1 | 2003 | 325 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 5778 | 0.190 |
Why?
|
| Moyamoya Disease | 1 | 2021 | 42 | 0.190 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2023 | 173 | 0.190 |
Why?
|
| Trachea | 1 | 2003 | 298 | 0.180 |
Why?
|
| Disposable Equipment | 1 | 2020 | 22 | 0.180 |
Why?
|
| alpha-Synuclein | 1 | 2021 | 118 | 0.180 |
Why?
|
| Regional Blood Flow | 1 | 2021 | 285 | 0.180 |
Why?
|
| Mice, Nude | 4 | 2018 | 4329 | 0.180 |
Why?
|
| tau Proteins | 1 | 2022 | 214 | 0.180 |
Why?
|
| Age Determination by Skeleton | 1 | 2019 | 10 | 0.180 |
Why?
|
| Finger Phalanges | 1 | 2019 | 5 | 0.170 |
Why?
|
| Nasopharynx | 1 | 2020 | 117 | 0.170 |
Why?
|
| Aortic Rupture | 1 | 2021 | 115 | 0.170 |
Why?
|
| Structure-Activity Relationship | 2 | 2021 | 979 | 0.170 |
Why?
|
| Pregnancy | 5 | 2022 | 8125 | 0.170 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2021 | 160 | 0.170 |
Why?
|
| Carrier Proteins | 2 | 2005 | 2100 | 0.170 |
Why?
|
| Neuroprotective Agents | 1 | 2021 | 219 | 0.170 |
Why?
|
| Appendicitis | 1 | 2021 | 177 | 0.170 |
Why?
|
| Nanotechnology | 3 | 2009 | 137 | 0.170 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 103 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 327 | 0.160 |
Why?
|
| Image Enhancement | 3 | 2008 | 553 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 4 | 2021 | 7103 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2019 | 1689 | 0.160 |
Why?
|
| Mouth Neoplasms | 2 | 2023 | 734 | 0.160 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 247 | 0.160 |
Why?
|
| Placentation | 1 | 2019 | 61 | 0.160 |
Why?
|
| Protein Binding | 2 | 2018 | 3485 | 0.160 |
Why?
|
| Binding, Competitive | 2 | 2012 | 329 | 0.160 |
Why?
|
| Limit of Detection | 1 | 2018 | 85 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 2222 | 0.160 |
Why?
|
| Solubility | 1 | 2018 | 247 | 0.160 |
Why?
|
| Aortic Aneurysm | 1 | 2021 | 218 | 0.160 |
Why?
|
| Iodine | 2 | 2016 | 55 | 0.150 |
Why?
|
| Tumor Burden | 4 | 2021 | 2033 | 0.150 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2018 | 127 | 0.150 |
Why?
|
| Child Abuse | 1 | 2021 | 208 | 0.150 |
Why?
|
| Molecular Conformation | 1 | 2018 | 158 | 0.150 |
Why?
|
| Brain Diseases | 1 | 2021 | 412 | 0.140 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 12028 | 0.140 |
Why?
|
| Membranes, Artificial | 1 | 2017 | 39 | 0.140 |
Why?
|
| Chickens | 1 | 2017 | 783 | 0.140 |
Why?
|
| Materials Testing | 1 | 2017 | 119 | 0.140 |
Why?
|
| Male | 17 | 2022 | 128400 | 0.140 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 4963 | 0.140 |
Why?
|
| Molecular Structure | 2 | 2021 | 530 | 0.130 |
Why?
|
| Chitosan | 1 | 2017 | 85 | 0.130 |
Why?
|
| Models, Animal | 1 | 2019 | 657 | 0.130 |
Why?
|
| Gadolinium DTPA | 2 | 2007 | 173 | 0.130 |
Why?
|
| Cattle | 1 | 2017 | 836 | 0.130 |
Why?
|
| Echo-Planar Imaging | 1 | 2016 | 74 | 0.130 |
Why?
|
| Infant | 4 | 2021 | 13989 | 0.130 |
Why?
|
| Hydrogels | 1 | 2017 | 134 | 0.130 |
Why?
|
| Pericardium | 1 | 2017 | 146 | 0.130 |
Why?
|
| Rabbits | 3 | 2007 | 1028 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2007 | 218 | 0.130 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2015 | 17 | 0.120 |
Why?
|
| Child, Preschool | 4 | 2021 | 17049 | 0.120 |
Why?
|
| Organometallic Compounds | 2 | 2016 | 209 | 0.120 |
Why?
|
| Gestational Age | 1 | 2019 | 1174 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 5071 | 0.120 |
Why?
|
| Life Expectancy | 1 | 2015 | 129 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2021 | 2848 | 0.120 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 1710 | 0.120 |
Why?
|
| Retinal Dehydrogenase | 1 | 2014 | 85 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2022 | 625 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2023 | 999 | 0.120 |
Why?
|
| Drug Compounding | 2 | 2011 | 73 | 0.120 |
Why?
|
| Heterografts | 1 | 2016 | 739 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2022 | 700 | 0.120 |
Why?
|
| Fanconi Anemia | 1 | 2014 | 90 | 0.110 |
Why?
|
| Whole Body Imaging | 2 | 2012 | 120 | 0.110 |
Why?
|
| Models, Economic | 1 | 2013 | 102 | 0.110 |
Why?
|
| Models, Molecular | 1 | 2018 | 1742 | 0.110 |
Why?
|
| Disease Progression | 2 | 2021 | 6855 | 0.110 |
Why?
|
| Phosphatidylethanolamines | 1 | 2012 | 63 | 0.110 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 550 | 0.100 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2007 | 87 | 0.100 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 325 | 0.100 |
Why?
|
| Molecular Imaging | 2 | 2016 | 186 | 0.100 |
Why?
|
| Drug Design | 2 | 2021 | 371 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2015 | 402 | 0.100 |
Why?
|
| Fetus | 1 | 2016 | 674 | 0.100 |
Why?
|
| Cell Line, Tumor | 7 | 2016 | 14838 | 0.100 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 5171 | 0.100 |
Why?
|
| Concanavalin A | 1 | 2012 | 63 | 0.100 |
Why?
|
| Apolipoproteins E | 1 | 2013 | 220 | 0.100 |
Why?
|
| Biomarkers | 2 | 2022 | 5060 | 0.100 |
Why?
|
| Isoenzymes | 1 | 2014 | 651 | 0.100 |
Why?
|
| Time Factors | 6 | 2022 | 13021 | 0.100 |
Why?
|
| Coordination Complexes | 1 | 2011 | 17 | 0.100 |
Why?
|
| Dextrans | 1 | 2012 | 98 | 0.100 |
Why?
|
| Administration, Intravenous | 1 | 2012 | 248 | 0.100 |
Why?
|
| Triage | 1 | 2013 | 256 | 0.100 |
Why?
|
| Sodium Chloride | 1 | 2012 | 159 | 0.100 |
Why?
|
| Myocardium | 1 | 2017 | 1233 | 0.090 |
Why?
|
| Uterus | 1 | 2016 | 798 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 318 | 0.090 |
Why?
|
| Aptamers, Nucleotide | 1 | 2011 | 58 | 0.090 |
Why?
|
| Immunocompetence | 1 | 2011 | 73 | 0.090 |
Why?
|
| Doxorubicin | 3 | 2009 | 3145 | 0.090 |
Why?
|
| Risk | 1 | 2015 | 1940 | 0.090 |
Why?
|
| Biological Transport | 1 | 2012 | 627 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 2 | 2016 | 2455 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2015 | 1042 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 768 | 0.090 |
Why?
|
| Equipment Design | 1 | 2013 | 1209 | 0.090 |
Why?
|
| Residence Characteristics | 2 | 2023 | 357 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2012 | 634 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 601 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 10706 | 0.090 |
Why?
|
| Surface Properties | 1 | 2009 | 189 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 965 | 0.080 |
Why?
|
| Antineoplastic Agents | 5 | 2011 | 14616 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 607 | 0.080 |
Why?
|
| Flow Cytometry | 2 | 2013 | 3045 | 0.080 |
Why?
|
| Capillary Permeability | 1 | 2009 | 116 | 0.080 |
Why?
|
| Retrospective Studies | 8 | 2023 | 39834 | 0.080 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 631 | 0.080 |
Why?
|
| HeLa Cells | 1 | 2012 | 1685 | 0.080 |
Why?
|
| Folate Receptors, GPI-Anchored | 2 | 2005 | 58 | 0.080 |
Why?
|
| Radiographic Image Enhancement | 1 | 2011 | 410 | 0.080 |
Why?
|
| Pandemics | 3 | 2022 | 1610 | 0.080 |
Why?
|
| Lipids | 1 | 2012 | 654 | 0.080 |
Why?
|
| Cell Survival | 2 | 2012 | 3063 | 0.070 |
Why?
|
| Cell Line | 2 | 2013 | 5339 | 0.070 |
Why?
|
| Technology, Pharmaceutical | 1 | 2007 | 28 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 3604 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 2 | 2014 | 4140 | 0.070 |
Why?
|
| Capsules | 1 | 2007 | 54 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2013 | 2363 | 0.070 |
Why?
|
| Comorbidity | 1 | 2013 | 2392 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2014 | 5591 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 242 | 0.070 |
Why?
|
| Hippocampus | 1 | 2012 | 973 | 0.070 |
Why?
|
| Macrophages | 1 | 2013 | 1352 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 7665 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 1585 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2007 | 161 | 0.060 |
Why?
|
| Mammography | 2 | 2009 | 1052 | 0.060 |
Why?
|
| Prevalence | 1 | 2013 | 3403 | 0.060 |
Why?
|
| Adult | 4 | 2023 | 81998 | 0.060 |
Why?
|
| Urethane | 1 | 2004 | 15 | 0.060 |
Why?
|
| Spine | 1 | 2007 | 312 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2012 | 1564 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2007 | 293 | 0.060 |
Why?
|
| Autophagy | 1 | 2011 | 911 | 0.060 |
Why?
|
| Risk Factors | 1 | 2021 | 17901 | 0.060 |
Why?
|
| Respiratory Transport | 1 | 2003 | 2 | 0.060 |
Why?
|
| Bronchography | 1 | 2003 | 24 | 0.060 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2003 | 24 | 0.050 |
Why?
|
| Drug Stability | 1 | 2003 | 106 | 0.050 |
Why?
|
| Finite Element Analysis | 1 | 2003 | 55 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 342 | 0.050 |
Why?
|
| Pulmonary Ventilation | 1 | 2003 | 49 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2023 | 78 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 466 | 0.050 |
Why?
|
| Cadaver | 1 | 2003 | 202 | 0.050 |
Why?
|
| Texas | 1 | 2013 | 6447 | 0.050 |
Why?
|
| Radiography, Abdominal | 1 | 2003 | 126 | 0.050 |
Why?
|
| Hospitalization | 2 | 2022 | 2168 | 0.050 |
Why?
|
| Protein Aggregates | 1 | 2021 | 26 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2006 | 1271 | 0.050 |
Why?
|
| Policy | 1 | 2021 | 52 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2013 | 6768 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 340 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 99 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 323 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2021 | 76 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 4795 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2023 | 469 | 0.040 |
Why?
|
| Protein Folding | 1 | 2021 | 297 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 133 | 0.040 |
Why?
|
| Adolescent | 4 | 2022 | 32744 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2021 | 112 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2021 | 198 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 314 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2021 | 387 | 0.040 |
Why?
|
| Blood Volume | 1 | 2019 | 107 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 417 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 6193 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 179 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2021 | 247 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 929 | 0.040 |
Why?
|
| Body Composition | 1 | 2022 | 607 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2022 | 950 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 363 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 738 | 0.040 |
Why?
|
| Hepatitis B Antibodies | 1 | 1997 | 57 | 0.040 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1997 | 89 | 0.030 |
Why?
|
| Polyesters | 1 | 2017 | 68 | 0.030 |
Why?
|
| Meglumine | 1 | 2016 | 21 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 10385 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2016 | 90 | 0.030 |
Why?
|
| Rest | 1 | 2016 | 69 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 1469 | 0.030 |
Why?
|
| Critical Care | 1 | 2022 | 799 | 0.030 |
Why?
|
| Logistic Models | 1 | 2023 | 3448 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2012 | 1401 | 0.030 |
Why?
|
| Radiometry | 1 | 2021 | 1018 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2021 | 932 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 2196 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2020 | 1309 | 0.030 |
Why?
|
| Mutation | 1 | 2015 | 15911 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 965 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2021 | 1933 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 1292 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2014 | 63 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 105 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 5569 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2022 | 2238 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 3919 | 0.030 |
Why?
|
| Cell Death | 2 | 2008 | 686 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 850 | 0.030 |
Why?
|
| Aged | 2 | 2024 | 73383 | 0.030 |
Why?
|
| United States | 2 | 2021 | 15856 | 0.030 |
Why?
|
| Hydrodynamics | 1 | 2011 | 18 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 4958 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2014 | 376 | 0.020 |
Why?
|
| Magnetics | 1 | 2011 | 98 | 0.020 |
Why?
|
| Amides | 1 | 2011 | 115 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2011 | 70 | 0.020 |
Why?
|
| Beclin-1 | 1 | 2011 | 88 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 606 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 353 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2011 | 474 | 0.020 |
Why?
|
| Middle Aged | 2 | 2014 | 90348 | 0.020 |
Why?
|
| Algorithms | 1 | 2021 | 3900 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2009 | 42 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2011 | 5698 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 1125 | 0.020 |
Why?
|
| X-Rays | 1 | 2009 | 151 | 0.020 |
Why?
|
| Phospholipids | 1 | 2009 | 167 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 622 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 266 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2007 | 61 | 0.020 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2009 | 236 | 0.020 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2007 | 24 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 2007 | 69 | 0.020 |
Why?
|
| KB Cells | 1 | 2006 | 21 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 1457 | 0.020 |
Why?
|
| Blood | 1 | 2007 | 170 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 142 | 0.020 |
Why?
|
| Proteins | 1 | 2014 | 2043 | 0.020 |
Why?
|
| Veins | 1 | 2007 | 165 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2006 | 239 | 0.020 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 61 | 0.020 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 194 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2009 | 704 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 1571 | 0.020 |
Why?
|
| Arteries | 1 | 2007 | 291 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2011 | 1038 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 2320 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2011 | 2422 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1997 | 4480 | 0.010 |
Why?
|
| Artifacts | 1 | 2007 | 536 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 1267 | 0.010 |
Why?
|
| Chick Embryo | 1 | 2003 | 220 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 4831 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2007 | 521 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 1579 | 0.010 |
Why?
|
| Computational Biology | 1 | 2007 | 1293 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 5310 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 3656 | 0.010 |
Why?
|
| Carcinoma | 1 | 2011 | 2609 | 0.010 |
Why?
|
| Phenotype | 1 | 2011 | 6516 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 9041 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 7237 | 0.010 |
Why?
|
| Glioma | 1 | 2009 | 1978 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2008 | 9290 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 7754 | 0.010 |
Why?
|
| Culture Media | 1 | 1997 | 343 | 0.010 |
Why?
|
| Perfusion | 1 | 1997 | 285 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1997 | 359 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 33741 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 1525 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 12102 | 0.010 |
Why?
|
| Prognosis | 1 | 2008 | 22481 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 16205 | 0.000 |
Why?
|